TMDX Maintained by Canaccord Genuity -- Price Target Lowered to $94

gurufocus.com · 2026-10-13

TransMedics Group (TMDX) Analyst Rating Update On October 13, 2026, Canaccord Genuity maintained a "Buy" rating on TransMedics Group (TMDX) while adjusting t

TickrTrends take: Canaccord Genuity's reduction of its price target to $94 occurs within a context where TickrTrends currently identifies TMDX as undervalued, suggesting the market may not yet be pricing in the full value of the Healthcare company's assets or earnings potential. A valuation-focused reader should monitor whether this analyst action represents a broader market reassessment that could narrow the gap between current pricing and intrinsic value estimates. The maintenance rating alongside the lowered target warrants attention to whether upcoming earnings or operational metrics might validate or challenge the undervalued designation.

Read the full story at gurufocus.com →